文献速递湿疹皮炎与荨麻疹

度普利尤单抗联合外用糖皮质激素治疗环孢素A应答不足或不耐受的成人特应性皮炎:LIBERTY AD CAFÉ III期试验

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
PubMed 文献 · Br J Dermatol · 2018-03-25

LIBERTY AD CAFÉ是一项16周双盲随机安慰剂对照III期试验,纳入对环孢素A应答不足/不耐受或医学上不宜使用环孢素A的成人特应性皮炎患者325例。两组不良事件总体发生率相似,度普利尤单抗组结膜炎更常见,安慰剂组皮肤感染更常见。

要点

  • 度普利尤单抗联合外用糖皮质激素显著提高环孢素A应答不足/不耐受成人特应性皮炎的EASI-75应答率
  • 每周和每两周给药方案疗效相当,均显著优于安慰剂联合外用糖皮质激素
  • 度普利尤单抗组结膜炎更常见,安慰剂组皮肤感染更常见,总体安全性无新信号

核心结论

  • 度普利尤单抗联合外用糖皮质激素显著改善有环孢素A应答不足/不耐受史或医学上不宜使用环孢素A的成人特应性皮炎患者的体征、症状和生活质量。
  • 未发现新的安全性信号。

研究设计与样本

  • 16周双盲、随机、安慰剂对照III期试验(LIBERTY AD CAFÉ)。
  • 390例患者筛查,325例随机分组,318例完成试验。
  • 患者按1:1:1随机接受皮下度普利尤单抗300 mg每周、每两周或安慰剂,所有患者从第-2周至第16周接受中效外用糖皮质激素。

主要发现

  • 度普利尤单抗每周和每两周联合外用糖皮质激素组在其他临床结局和特应性皮炎症状(包括瘙痒、疼痛、睡眠障碍、焦虑和抑郁症状及生活质量)方面均显著改善。
  • 度普利尤单抗联合外用糖皮质激素组结膜炎更常见,安慰剂联合外用糖皮质激素组皮肤感染更常见。

关键数值与推荐

  • 主要终点为第16周EASI较基线改善≥75%的患者比例。
  • 度普利尤单抗300 mg皮下注射,每周或每两周一次,联合中效外用糖皮质激素。

临床怎么用

  • 对于对环孢素A应答不足/不耐受或医学上不宜使用环孢素A的成人中重度特应性皮炎患者,可考虑度普利尤单抗联合外用糖皮质激素治疗。
  • 度普利尤单抗每周和每两周给药方案均可选择,疗效和安全性相似。
  • 治疗期间需关注结膜炎的发生,安慰剂组皮肤感染更常见提示度普利尤单抗可能降低皮肤感染风险。

局限性

  • 试验为期16周,长期疗效和安全性未报告。
  • 研究人群限定为对环孢素A应答不足/不耐受或医学上不宜使用环孢素A的成人患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults. OBJECTIVES: To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. METHODS: In this 16-week, double-blind, randomized, placebo-controlled, phase III trial, patients were randomized 1 : 1 : 1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo. All received concomitant medium-potency TCS from Week -2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS. RESULTS: In total, 390 patients were screened, 325 were randomized, and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients in the dupilumab qw + TCS and q2w + TCS groups achieved ≥ 75% improvement from baseline in the Eczema Area and Severity Index at Week 16 vs. the placebo + TCS group (primary end point) (59·1% and 62·6% vs. 29·6%, respectively; P < 0·001 vs. placebo + TCS, both doses). Other clinical outcomes and atopic dermatitis symptoms were significantly improved in the dupilumab qw + TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69·1%, 72·0% and 69·4%, respectively) and serious adverse events (1·8%, 1·9% and 1·9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS. CONCLUSIONS: Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018. PMID: 29193016. doi:10.1111/bjd.16156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。